CAMBRIDGE, England, June 10, 2015 /PRNewswire/ --

Aegate, the leader in medicine verification and authentication services, is pleased to announce an important opportunity in Frankfurt on the 24^th and 25^th June.

     (Logo: http://photos.prnewswire.com/prnh/20150610/748687 )

The Falsified Medicine Directive heralds a new era of value creation that the Pharmacists in Germany and all over Europe can harness, the Aegate Symposium will enable all software providers which serve pharmacies to immediately start a new set of services and benefit from its related revenues stream.

Aegate are the global leaders in medicine verification and a qualified Blueprint Provider with the European Medicines Verification Organisation.

Germany has set a governance model for the authentication process and the stakeholders have choice in which service provider to implement this legislation with.

The Aegate model has been successfully tested by over 20,000 pharmacy dispensing points in the last 8 years in several European countries. The revenue and positive overall impact for both the pharmacy and the service provider has been seen to increase patient safety by stopping 1.8 Million medicines which should not have been dispensed and improve the profits of the pharmacy and of the software providers.

Aegate certification in a pharmacy means quality. Are your pharmacies Aegate Ready? Is your software Aegate ready?

Join the symposium by registering via http://aegate.com/en/aegate-safe-medicine-ecosystem-partner-program-symposium-on-24th-25th-june-2015-in-frankfurt/

About Aegate 

With a documented history of some 3.3 billion medicines scanned to date with an average rate of 200,000 transactions per hour across 18,000 dispensing points, Aegate is the principal active market leader in medicines verification. Aegate's Reach, Assure and Protect services meets the needs of all stakeholders. Supported internationally by manufacturers and pharmacists alike, Aegate is a European company with offices throughout Europe. Our mission is to protect patients from falsified, recalled or expired medicines.

We operate a highly secure real‐time system to verify the authenticity of medicines. This operates seamlessly from manufacturer to pharmacy, and fully meets the requirements of European legislation for falsified medicines. The Aegate network also supports messaging services that provide additional information for the pharmacist at the point of dispense, such as regulatory or drug safety advice and patient education or adherence information.

For more information on Aegate, please visit http://www.aegate.com

Media contact information: Miriam Foster
Head of Marketing & Communications
Miriam.Foster@aegate.com
T: +44-1763-268160

W: http://www.aegate.com

SOURCE Aegate